Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence
Bausch Health (NYSE:BHC) and its gastroenterology business, Salix Pharmaceuticals, have launched a new direct-to-consumer campaign called "I Wish I Knew" for their FDA-approved drug Xifaxan庐 (rifaximin). The campaign aims to educate about overt hepatic encephalopathy (OHE), a serious complication affecting cirrhosis patients.
The initiative features a 60-second spot highlighting a patient's journey with OHE and treatment with Xifaxan, alongside three new patient testimonials. The campaign emphasizes that up to 80% of cirrhosis patients may develop some form of hepatic encephalopathy, which can cause alterations in consciousness, cognition, and behavior.
The company is collaborating with patient advocacy organizations including Global Liver Institute and American Liver Foundation to raise awareness about chronic liver disease progression and OHE management.
Bausch Health (NYSE:BHC) e la sua divisione gastroenterologica, Salix Pharmaceuticals, hanno lanciato una nuova campagna diretta ai consumatori intitolata "I Wish I Knew" per il loro farmaco approvato dalla FDA Xifaxan庐 (rifaximina). La campagna ha l'obiettivo di sensibilizzare sull'encefalopatia epatica overt (OHE), una grave complicanza che colpisce i pazienti con cirrosi.
L'iniziativa presenta uno spot di 60 secondi che racconta il percorso di un paziente affetto da OHE e il trattamento con Xifaxan, insieme a tre nuove testimonianze di pazienti. La campagna sottolinea che fino all'80% dei pazienti con cirrosi pu貌 sviluppare una qualche forma di encefalopatia epatica, che pu貌 causare alterazioni della coscienza, della cognizione e del comportamento.
L'azienda collabora con organizzazioni di advocacy per i pazienti, tra cui il Global Liver Institute e l'American Liver Foundation, per aumentare la consapevolezza sulla progressione della malattia epatica cronica e sulla gestione dell'OHE.
Bausch Health (NYSE:BHC) y su divisi贸n de gastroenterolog铆a, Salix Pharmaceuticals, han lanzado una nueva campa帽a directa al consumidor llamada "I Wish I Knew" para su medicamento aprobado por la FDA Xifaxan庐 (rifaximina). La campa帽a tiene como objetivo educar sobre la encefalopat铆a hep谩tica overt (OHE), una complicaci贸n grave que afecta a pacientes con cirrosis.
La iniciativa incluye un spot de 60 segundos que destaca el recorrido de un paciente con OHE y el tratamiento con Xifaxan, junto con tres nuevos testimonios de pacientes. La campa帽a enfatiza que hasta el 80% de los pacientes con cirrosis pueden desarrollar alguna forma de encefalopat铆a hep谩tica, que puede causar alteraciones en la conciencia, la cognici贸n y el comportamiento.
La compa帽铆a colabora con organizaciones de defensa de pacientes, como Global Liver Institute y American Liver Foundation, para aumentar la conciencia sobre la progresi贸n de la enfermedad hep谩tica cr贸nica y la gesti贸n de la OHE.
Bausch Health (NYSE:BHC)鞕� 攴� 鞙勳灔氤� 靷梾攵�鞚� Salix Pharmaceuticals電� FDA 鞀轨澑 鞎诫鞚� Xifaxan庐 (毽實鞁滊)鞚� 鞙勴暅 "I Wish I Knew"霛茧姅 靸堧鞖� 歆侅爲 靻岆箘鞛� 雽�靸� 旌犿帢鞚胳潉 鞁滌瀾頄堨姷雼堧嫟. 鞚� 旌犿帢鞚胳潃 臧勱步氤� 頇橃瀽鞐愱矊 鞁皝頃� 頃╇硲歃濎澑 氇呺氨頃� 臧勳劚雵岆硲歃�(OHE)鞐� 雽�頃� 甑愳湣頃橂姅 瓴冹潉 氇╉憸搿� 頃╇媹雼�.
鞚� 旌犿帢鞚胳棎電� OHE 頇橃瀽鞚� 鞐爼瓿� Xifaxan 旃橂毳� 臧曥“頃橂姅 60齑� 攵勲焿鞚� 甏戧碃鞕� 靹� 氇呾潣 靸堧鞖� 頇橃瀽 歃濎柛鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟. 旌犿帢鞚胳潃 臧勱步氤� 頇橃瀽鞚� 斓滊寑 80%臧� 臧勳劚雵岆硲歃濎潣 鞏措枻 順曧儨毳� 瓴潉 靾� 鞛堨溂氅�, 鞚措姅 鞚橃嫕, 鞚胳 氚� 頄夒彊鞚� 氤�頇旊ゼ 齑堧灅頃� 靾� 鞛堨潓鞚� 臧曥“頃╇媹雼�.
須岇偓電� Global Liver Institute 氚� American Liver Foundation鞚� 韽暔頃� 頇橃瀽 鞓鬼樃 雼泊霌り臣 順戨牓頃橃棳 毵岇劚 臧� 歆堩櫂 歆勴枆瓿� OHE 甏�毽棎 雽�頃� 鞚胳嫕鞚� 雴掛澊瓿� 鞛堨姷雼堧嫟.
Bausch Health (NYSE:BHC) et sa division gastroent茅rologie, Salix Pharmaceuticals, ont lanc茅 une nouvelle campagne directe aupr猫s des consommateurs intitul茅e "I Wish I Knew" pour leur m茅dicament approuv茅 par la FDA, Xifaxan庐 (rifaximine). Cette campagne vise 脿 sensibiliser 脿 l'enc茅phalopathie h茅patique manifeste (OHE), une complication grave affectant les patients atteints de cirrhose.
L'initiative comprend un spot de 60 secondes mettant en lumi猫re le parcours d'un patient souffrant d'OHE et son traitement avec Xifaxan, ainsi que trois nouveaux t茅moignages de patients. La campagne souligne que jusqu'脿 80 % des patients atteints de cirrhose peuvent d茅velopper une forme d'enc茅phalopathie h茅patique, pouvant entra卯ner des alt茅rations de la conscience, des fonctions cognitives et du comportement.
L'entreprise collabore avec des associations de d茅fense des patients, notamment le Global Liver Institute et l'American Liver Foundation, afin de sensibiliser 脿 la progression des maladies chroniques du foie et 脿 la gestion de l'OHE.
Bausch Health (NYSE:BHC) und sein Gastroenterologie-Gesch盲ftsbereich Salix Pharmaceuticals haben eine neue Direkt-zu-Verbraucher-Kampagne namens "I Wish I Knew" f眉r ihr von der FDA zugelassenes Medikament Xifaxan庐 (Rifaximin) gestartet. Die Kampagne soll 眉ber die manifeste hepatische Enzephalopathie (OHE) aufkl盲ren, eine ernste Komplikation bei Patienten mit Zirrhose.
Die Initiative umfasst einen 60-sek眉ndigen Spot, der den Weg eines Patienten mit OHE und der Behandlung mit Xifaxan zeigt, sowie drei neue Patientenberichte. Die Kampagne betont, dass bis zu 80 % der Zirrhose-Patienten eine Form der hepatischen Enzephalopathie entwickeln k枚nnen, die Bewusstseins-, Kognitions- und Verhaltens盲nderungen verursachen kann.
Das Unternehmen arbeitet mit Patientenvertretungen wie dem Global Liver Institute und der American Liver Foundation zusammen, um das Bewusstsein f眉r den Fortschritt chronischer Lebererkrankungen und das Management von OHE zu erh枚hen.
- First and only FDA-approved medicine for reducing OHE recurrence risk
- Strong market positioning through educational campaign and patient advocacy partnerships
- Addresses a significant medical need affecting up to 80% of cirrhosis patients
- Competitive pressure in the gastroenterology market
- Dependent on successful patient education and awareness for market penetration
Focused on highlighting real patient experiences, Salix continues to lead the charge in educating and advocating for the hepatic encephalopathy community
LAVAL, QC / / July 7, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced its new direct-to-consumer (DTC) "I Wish I Knew" campaign for Xifaxan庐 (rifaximin), the first and only medicine FDA approved for the reduction in risk of overt hepatic encephalopathy (OHE) recurrence in adults. Designed to raise awareness about OHE and the role of Xifaxan, "I Wish I Knew" seeks to educate and empower patients and caregivers to take proactive steps in managing their liver disease.
In patients with cirrhosis, overt hepatic encephalopathy (OHE) is one of the key complications that is associated with worsening outcomes, morbidity, and mortality.1 In cirrhosis a damaged liver does not function normally, leading to toxins from the gut entering the bloodstream, and traveling to the brain, which can cause damage, some of which may be irreversible. These OHE episodes may present as alterations in consciousness, cognition, and behavior.2,3 Up to
Salix remains steadfast in its mission to educate, empower and provide solutions for individuals at risk for recurrence of OHE. The new 60-second "I Wish I Knew" spot tells the story of a woman with a history of OHE, who reflects on her experience with symptoms of disorientation and confusion. She "wasn't herself" during this time, but over the course of her treatment with Xifaxan, she experienced a reduction in risk of her OHE episodes.
"We want people to know that the risk of recurring OHE episodes can be managed despite the complex nature of the condition," said Aimee Lenar, Executive Vice President of US Pharma at Bausch Health. "Salix aims to spread knowledge about the progression of chronic liver disease (CLD) to cirrhosis and overt hepatic encephalopathy. Our hope is for a future where fewer patients and loved ones 'wish they knew' cirrhosis could affect their brain, and more patients can access the care they need sooner."
Salix is dedicated to amplifying patient voices and bringing authentic experiences to the forefront of the OHE community. In addition to ongoing efforts with patient advocacy organizations including Global Liver Institute (GLI) and American Liver Foundation (ALF), Salix also recently unveiled three patient stories. These testimonials feature real, lived experiences with OHE and Xifaxan, offering diverse perspectives about managing the condition and providing hope for others battling OHE.
Click to see the new spot and hear patient stories about managing OHE.
##
About XIFAXAN
INDICATION
XIFAXAN庐 (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults.
IMPORTANT SAFETY INFORMATION
XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.
Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.
In clinical studies, the most common adverse reactions for XIFAXAN (alone or in combination with lactulose) were:
HE (鈮�
10% ): Peripheral edema (17% ), constipation (16% ), nausea (15% ), fatigue (14% ), insomnia (14% ), ascites (13% ), dizziness (13% ), urinary tract infection (12% ), anemia (10% ), and pruritus (10% )INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.
XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.
To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or .
Please for full Prescribing Information.
About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. Our gastroenterology business, Salix Pharmaceuticals, is one of the largest specialty pharmaceutical businesses in the world and has licensed, developed and marketed innovative products for the treatment of gastrointestinal diseases for more than 30 years. For more information about Salix, visit and connect with us on and For more information about Bausch Health, visit and connect with us on .
References
Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715-735. doi:10.1002/hep.27210
Vince AJ, Burridge SM. Ammonia production by intestinal bacteria: the effects of lactose, lactulose and glucose. J Med Microbiol. 1980;13(2):177-191. doi:10.1099/00222615-13-2-177
Khan A, Ayub M, Khan WM. Hyperammonemia is associated with increasing severity of both liver cirrhosis and hepatic encephalopathy. Int J Hepatol. 2016;2016:6741754. doi:10.1155/2016/6741754
##
漏2025 Salix Pharmaceuticals or its affiliates.
Investor Contact: | Media Contact: |
SOURCE: Bausch Health Companies Inc.
View the original on ACCESS Newswire
FAQ
What is the purpose of Bausch Health's new 'I Wish I Knew' campaign for Xifaxan?
How many cirrhosis patients are affected by hepatic encephalopathy (HE)?
What organizations is Bausch Health (BHC) partnering with for OHE awareness?
What are the symptoms of overt hepatic encephalopathy that Xifaxan treats?
How is Bausch Health (BHC) promoting patient education about Xifaxan?
